{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T22:38:58Z","timestamp":1775083138728,"version":"3.50.1"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2016,8,22]],"date-time":"2016-08-22T00:00:00Z","timestamp":1471824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005615","name":"Beth Israel Deaconess Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005615","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>Despite guideline recommendations, baseline laboratory testing and advanced imaging are widely ordered in clinical practice to stage asymptomatic patients with clinical stage II breast cancer (BC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods.<\/jats:title>\n                  <jats:p>A retrospective study at two academic centers in Boston, Massachusetts, between 2006 and 2007 explored the use, results, and implications of laboratory tests, tumor markers, and imaging in patients with clinical stage II BC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Among 411 patients, 233 (57%) had liver function testing, 134 (33%) had tumor marker tests, and 237 (58%) had computed tomography (CT) as part of their initial diagnostic workup. Median age was 52 (range, 23\u201390 years). On multivariable analysis, young age, more advanced stage, and tumor subtype (human epidermal growth receptor-positive [HER2+] and triple-negative breast cancer [TNBC]) were significantly associated with baseline CT. The rate of detection of true metastatic disease with use of baseline staging imaging was 2.1% (95% confidence interval, 0.7%\u20135%). It was 2.2% (3 of 135) for estrogen receptor\/progesterone receptor-positive disease, 1.9% (1 of 54) for HER2+ disease, and 2.1% (1 of 48) for TNBC. At 5 years of follow-up, 46 of 406 patients were diagnosed with metastatic breast cancer. Thirty-four of 46 (73.9%) who developed recurrent disease had imaging at their initial diagnosis, and of these, five had abnormalities on their initial imaging that was correlated with where they developed metastatic disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>In this cohort of women with stage II BC, staging imaging at diagnosis had a low yield in detecting distant metastases (2.1%). The detection rate was not higher with HER2+ disease or TNBC, despite the trend that patients with these subtypes were more likely to undergo imaging.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2016-0157","type":"journal-article","created":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T02:18:47Z","timestamp":1471918727000},"page":"1495-1501","source":"Crossref","is-referenced-by-count":6,"title":["Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer"],"prefix":"10.1093","volume":"21","author":[{"given":"Brittany L.","family":"Bychkovsky","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Guo","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jazmine","family":"Sutton","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Spring","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Faig","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibiayi","family":"Dagogo-Jack","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Battelli","sequence":"additional","affiliation":[{"name":"New England Cancer Specialists, Scarborough, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Jane","family":"Houlihan","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsai-Chu","family":"Yeh","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Medicine, National Yang-Ming University, Taipei, Taiwan, Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven E.","family":"Come","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,8,22]]},"reference":[{"key":"2021122309580950200_B1","volume-title":"NCCN clinical practice guidelines in oncology. Breast cancer. Version 3.2015","author":"National Comprehensive Cancer Network (NCCN)"},{"key":"2021122309580950200_B2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1245\/s10434-012-2571-4","article-title":"Advanced imaging modalities in early stage breast cancer: Preoperative use in the United States Medicare population","volume":"20","author":"Crivello","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"2021122309580950200_B3","doi-asserted-by":"crossref","first-page":"E387","DOI":"10.1503\/cmaj.150003","article-title":"Imaging for distant metastases in women with early-stage breast cancer: a population-based cohort study","volume":"187","author":"Simos","year":"2015","journal-title":"CMAJ"},{"key":"2021122309580950200_B4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jss.2015.02.065","article-title":"Staging studies have limited utility for newly diagnosed stage I-II breast cancer","volume":"196","author":"Linkugel","year":"2015","journal-title":"J Surg Res"},{"key":"2021122309580950200_B5","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1524-4741.2006.00343.x","article-title":"Bone scan and liver ultrasound scan in the preoperative staging for primary breast cancer","volume":"12","author":"Kasem","year":"2006","journal-title":"Breast J"},{"key":"2021122309580950200_B6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/2193-1801-3-176","article-title":"Patient perceptions and expectations regarding imaging for metastatic disease in early stage breast cancer","volume":"3","author":"Simos","year":"2014","journal-title":"Springerplus"},{"key":"2021122309580950200_B7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10549-015-3593-y","article-title":"Complete blood counts, liver function tests, and chest x-rays as routine screening in early-stage breast cancer: Value added or just cost","volume":"154","author":"Louie","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"2021122309580950200_B8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.breast.2011.10.005","article-title":"Evaluation of the evidence on staging imaging for detection of asymptomatic distant metastases in newly diagnosed breast cancer","volume":"21","author":"Brennan","year":"2012","journal-title":"Breast"},{"key":"2021122309580950200_B9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10549-011-1368-7","article-title":"The value of preoperative staging chest computed tomography to detect asymptomatic lung and liver metastasis in patients with primary breast carcinoma","volume":"126","author":"Kim","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"2021122309580950200_B10","first-page":"1","article-title":"Radiologic tests after a new diagnosis of breast cancer","volume":"3","author":"Dillman","year":"2000","journal-title":"Eff Clin Pract"},{"key":"2021122309580950200_B11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/annonc\/mdi063","article-title":"Baseline staging tests after a new diagnosis of breast cancer: Further evidence of their limited indications","volume":"16","author":"Puglisi","year":"2005","journal-title":"Ann Oncol"},{"key":"2021122309580950200_B12","volume-title":"Choosing Wisely. Cancer tests and treatments. 2012","author":"American Society of Clinical Oncology\/American Board of Internal Medicine"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2016-0157","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2016-0157","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/12\/1495\/41877212\/oncolo_21_12_1495.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/12\/1495\/41877212\/oncolo_21_12_1495.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T04:46:45Z","timestamp":1640321205000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/21\/12\/1495\/6401602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,22]]},"references-count":12,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,8,22]]},"published-print":{"date-parts":[[2016,12,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2016-0157","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,12,1]]},"published":{"date-parts":[[2016,8,22]]}}}